PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Status:
Completed
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of the
bone marrow in which excessive cells are produced.
Pembrolizumab also known as Keytruda is a drug that has recently been approved in the United
Stated by the Food and Drug Administration (FDA) for the treatment of patients with
unresectable or metastatic melanoma and disease progression. Pembrolizumab is experimental in
the treatment of MPN. The researchers want to find out what effects, good and /or bad it has
on participants and the disease.
Participants qualify to take part in this research study if have been diagnosed with a MPN
blood disorder called myelofibrosis (MF). Accelerated (10-19% blasts in the blood or bone
marrow) and blast phase (>20% blasts in the blood or bone marrow) MPN has been a difficult
disease to treat. The term "blasts" refers to immature cells found in the bone marrow. They
are not fully developed, and therefore, do not yet carry out any particular function within
the body.
Funds for conducting this research are provided by Merck and Company, the manufacturer of the
study drug pembrolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
John Mascarenhas
Collaborators:
Massachusetts General Hospital Montefiore Medical Center